中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HBsAg阳性恶性肿瘤患者化疗后肝损伤及HBV再激活的临床分析

吴盛喜 许鸿鹞 黄河澄 林连兴 罗何三

吴盛喜, 许鸿鹞, 黄河澄, 林连兴, 罗何三. HBsAg阳性恶性肿瘤患者化疗后肝损伤及HBV再激活的临床分析[J]. 临床肝胆病杂志, 2016, 32(1): 110-113. DOI: 10.3969/j.issn.1001-5256.2016.01.020
引用本文: 吴盛喜, 许鸿鹞, 黄河澄, 林连兴, 罗何三. HBsAg阳性恶性肿瘤患者化疗后肝损伤及HBV再激活的临床分析[J]. 临床肝胆病杂志, 2016, 32(1): 110-113. DOI: 10.3969/j.issn.1001-5256.2016.01.020
Wu ShengXi, Xu HongYao, Huang HeCheng, Lin LianXing, Luo HeSan. Clinical analysis of liver injury and hepatitis B virus reactivation after chemotherapy in HBsAg-positive patients with malignant tumors[J]. J Clin Hepatol, 2016, 32(1): 110-113. DOI: 10.3969/j.issn.1001-5256.2016.01.020
Citation: Wu ShengXi, Xu HongYao, Huang HeCheng, Lin LianXing, Luo HeSan. Clinical analysis of liver injury and hepatitis B virus reactivation after chemotherapy in HBsAg-positive patients with malignant tumors[J]. J Clin Hepatol, 2016, 32(1): 110-113. DOI: 10.3969/j.issn.1001-5256.2016.01.020

HBsAg阳性恶性肿瘤患者化疗后肝损伤及HBV再激活的临床分析

DOI: 10.3969/j.issn.1001-5256.2016.01.020
详细信息
  • 中图分类号: R512.62;R730.5

Clinical analysis of liver injury and hepatitis B virus reactivation after chemotherapy in HBsAg-positive patients with malignant tumors

  • 摘要: 目的探讨HBsAg阳性肿瘤患者化疗后肝损伤情况及HBV再激活的相关危险因素。方法收集2011年1月-2013年12月在汕头市中心医院接受化疗的HBsAg阳性的恶性肿瘤患者共150例。其中43例行预防性抗病毒治疗,即化疗前、化疗期间和化疗结束后半年使用抗病毒治疗(试验组),107例未行预防性抗病毒治疗(对照组)。回顾性分析2组患者化疗后肝损伤情况。计数资料组间比较采用χ2检验,使用Logistic回归分析法分析影响化疗后HBV再激活的相关因素。结果所有患者经过化疗,63例(42.0%)出现肝损伤,其中肝脏不良反应分级:Ⅰ度13例(8.7%)、Ⅱ度29例(19.3%)、Ⅲ度15例(10.0%)、Ⅳ度6例(4.0%),2组肝损伤程度差异具有统计学意义(χ2=19.498,P=0.001)。试验组肝损伤发生率为18.6%(8例),比对照组51.4%(55例)明显降低,差异有统计学意义(χ2=25.864,P<0.001)。Logistic单因素回归分析显示,化疗前乙型肝炎六项状态、HBV定量、是否使用激素及是否预防性使用抗病毒治疗差异具有统计学意义,将其纳入Logistic多因素回归分析...

     

  • [1]HU XL,ZHAO HW,WU XY,et al.Prevalence of hepatitis B virus infection[J].J Clin Hepatol,2012,28(6):413-421.(in Chinese)胡晓丽,赵宏伟,吴晓岩,等.乙型肝炎病毒感染的流行现状[J].临床肝胆病杂志,2012,28(6):413-421.
    [2]CHEN KL,CHEN J,RAO HL,et al.Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy:risk factors and survival[J].Chin J Cancer,2015,34(1):18.
    [3]LAW MF,LAI HK,CHAN HN,et al.The impact of hepatitis B virus(HBV)infection on clinical outcomes of patients with diffuse large B-cell lymphoma[J].Eur J Cancer Care(Engl),2015,24(1):117-124.
    [4]IFUKU H,KUSUMOTO S,TANAKA Y,et al.Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab[J].Hepatol Res,2015.[Epub ahead of print]
    [5]TANG SH,ZENG WZ,JIANG MD.American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].J Clin Hepatol,2014,31(4):483-485.(in Chinese)汤善宏,曾维政,蒋明德.2014年美国胃肠病学会指南:免疫抑制剂治疗过程中HBV再激活的预防及治疗[J].临床肝胆病杂志,2014,31(4):483-485.
    [6] YEO W,CHAN PK,ZHONG S,et al.Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factors[J].J Med Virol,2000,62(3):299-307.
    [7]WANG F,XU RH,LUO HY,et al.Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma[J].BMC Cancer,2008,8:115.
    [8]YEO W,CHAN PK,HO WM,et al.Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy[J].J Clin Oncol,2004,22(5):927-934.
    [9]LI YH,HE YF,WANG FH,et al.Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy[J].Chin J Cancer,2005,24(12):1507-1509.(in Chinese)李宇红,何义富,王风华,等.116例携带乙肝病毒的淋巴瘤患者化疗后发生肝功能损害的临床分析[J].癌症,2005,24(12):1507-1509.
    [10]TOTANI H,KUSUMOTO S,ISHIDA T,et al.Reactivation of hepatitis B virus(HBV)infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy[J].Int J Hematol,2015,101(4):398-404.
    [11]QU Q,SHEN KW.Hepatitis B virus reactivation in patients receiving chemotherapy with breast cancer[J].Chin J Hepatol,2012,92(34):2377-2378.
    [12]GUI HL,XIE Q.Diagnosis,management and prevention of hepatitis B virus reactivation during anticancer therapy[J].Chin J Hepatol,2007,15(1):78-80.(in Chinese)桂红莲,谢青.抗肿瘤治疗期间乙型肝炎再激活的诊断、治疗和预防[J].中华肝脏病杂志,2007,15(1):78-80.
    [13]LOK AS,LIANG RH,CHIU EK,et al.Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy.Report of a prospective study[J].Gastroenterology,1991,100(1):182-188.
    [14]PATTULLO V.Hepatitis B reactivation in the setting of chemotherapy and immunosuppression-prevention is better than cure[J].World J Hepatol,2015,7(7):954-967.
    [15]ZHONG S,YEO W,SCHRODER C,et al.High hepatitis B virus(HBV)DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy[J].J Viral Hepat,2004,11(1):55-59.
    [16]CHENG AL,HSIUNG CA,SU IJ,et al.Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV)reactivation in HBVcarriers with lymphoma[J].Hepatology,2003,37(6):1320-1328.
    [17]KIM E,YUNE S,HA JM,et al.Hepatitis B virus reactivation during anti-cancer chemotherapy in patients with past hepatitis B virus infection[J].Hepatogastroenterology,2014,61(134):1704-1711.
    [18]CHU CM,LIAW YF.Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B:a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline[J].J Hepatol,2005,43(3):411-417.
  • 加载中
计量
  • 文章访问数:  1887
  • HTML全文浏览量:  28
  • PDF下载量:  415
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-05-22
  • 刊出日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回